Curcumin [Turmeric] helps prevent prostate cancer. Prostate cancer is on a rise in India. But the good news is using turmeric regularly in food reduces chances of the disease.
A study conducted in Japan on curcumin, showed positive results in preventing as well as reversing prostate cancer.
Curcumin is used as a supplement in Japanese food. Indian food also use it as a spice. PSA went down by 50 per cent. High PSA can be either due to cancer or inflammation of the prostate. Curcumin can control both. Laboratory tests on cancerous cells also showed the curing effect of turmeric.
Soy was already known for its preventive quality. Turmeric has been added to the list now, he said. Japan and India have lower rate of prostate cancer compared to most western nations. Curcumin has played a role in it. But now as the incidence is increasing in these two countries, we need to find ways to prevent it.
A common use of curcumin in Japan is to control the hangover after excess intake of alcohol. It enhances liver enzymes which is good to digest alcohol. What people do not know is it helps in prevention of cancer.
The Incredible Health Benefits of Curcumin
Natural Anti inflammatory safer than Vioxx & Celebrex.
Protects brain cells from aging
Increases memory retention and clarity
Boosts overall cognitive function
Supports joint and muscle health
Promotes healthy cardiovascular function
Supports a healthy inflammatory response
Supports healthy mood balance
Promotes a healthy digestive system
Boosts detoxification and liver health
Supports natural weight loss
A new study from the Institute of Neuroscience and Medicine in Germany found a compound in turmeric a spice used in curry. can help the brain heal itself. Researchers injected the compound, called aromatic tumerone, into the brains of rats. Brain scans showed that the parts of the brain involved with nerve cell growth became more active. This leads to the thought that new cells might grow to repair a damaged brain.
The evidence is growing that curcumin, the substance in tumeric, should take a bigger role in the human diet for its ability to act as an antioxidant, anti-inflammatory and lipid lowering agent. Western Australian researcher, Gautam Sethi, from Curtin University (Australia), and his colleagues see strong potential, based on this scientific review of past clinical trials, for curcumin and cancer. To date the studies are small in scope, but Sethi and his team see evidence for larger studies. Published in Molecules, Vol. 20, No. 2, Feb 2015.
curcumin_Small-e1386707213948ABSTRACT: Despite significant advances in treatment modalities over the last decade, neither the incidence of the disease nor the mortality due to cancer has altered in the last thirty years, according to a new research review in curcumin. The researchers cite that available anti-cancer drugs exhibit limited efficacy, are associated with severe side effects, and they are also expensive. Thus identification of pharmacological agents that do not have these disadvantages is required. Curcumin, a polyphenolic compound derived from turmeric (Curcumin longa), is one such agent that has been extensively studied over the last three to four decades for its potential anti-inflammatory and/or anti-cancer effects.
Curcumin has been found to suppress initiation, progression, and metastasis of a variety of tumors. These anti-cancer effects are predominantly mediated through its negative regulation of various transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic molecules. It also abrogates proliferation of cancer cells by arresting them at different phases of the cell cycle and/or by inducing their apoptosis. The current review focuses on the diverse molecular targets modulated by curcumin that contribute to its efficacy against various human cancers.
Todays Practitioners registered users can access a summary of this research below. This content is gated for licensed practitioners only because of the nature of the content and our company standards for DSHEA regulatory compliance.
Curtin University adjunct research fellow Gautam Sethi says most diseases, including cancer, are caused by the deregulation of multiple genes. To treat cancer you need multi-targeted agents, better than mono-targeted agents, which have been used for the past few years, Associate Professor Sethi says. Multi-targeted agents are those that target more than one deregulated oncogenic signaling cascadesthey are more effective in treating cancer as it has been found that several genes are mutated in a given cancer. We can modulate several of such oncogenic genes, which are deregulated in cancer using curcumin.
A/Prof Sethi says curcumin is exceptionally effective for multiple myeloma patients and those suffering from the particularly lethal pancreatic cancer, for which there are no drugs. However, curcumin was not found to be as effective in breast cancer patients being treated with the chemotherapeutic agent cyclophosphamide. According to the research, curcumin can counteract the effect of cyclophosphamide.
Curcumin safe in high doses
A/Prof Sethi says curcumin is possibly the only drug that can be given at high dosesup to 12gwithout any toxicity. It can target most of the oncogenic proteins like NF-kB, STAT3, AP-1, he says.
A/Prof Sethi says the only known side effect of the agent is blood thinning, and therefore advises against taking curcumin if undergoing surgery. A/Prof Sethi says it would be ideal to combine curcumin with other drugs or natural compounds, like piperine, an alkaloid found in pepper to increase its bioavailabilty.
If we combine it with piperine we see viability increase by 2000 per cent 45 minutes after administering the curcumin, he says. A/Prof Sethi says there is a lack of data to explain the underlying mechanism of its effect, however, it is known for its anti-inflammatory effects. It has been shown that most chronic diseases, including cancer, are caused by inflammation and can be treated by anti-inflammatory agents.
He says more work needs to be done to improve curcumins viability, as body tissues quickly absorb it.
Study Excerpts for Multiple Myeloma and Pancreatic Cancer
(link at the bottom of this article for the full study and references)
The chemopreventive potential of curcumin in monoclonal gammopathy of undetermined significance (MGUS), a high-risk condition for progression to multiple myeloma, was tested by Golombick et al., in a cross-over study design . Out of 27 patients, 17 received 4000 mg of curcumin for 3 months before cross-over to placebo. The rest received placebo first, followed by curcumin. The levels of paraprotein and urinary N-telopeptide from type I collagen decreased in some patients. The same group reported beneficial effects of curcumin in MGUS in another randomized, double blind, placebo-controlled cross-over study . A phase I/II trial by Vadhan-Raj et al., in 29 patients with asymptomatic, relapsed, or plateau phase multiple myeloma showed a decrease in expression of NF-κB, COX-2, and STAT3 in peripheral blood mononuclear cells and stable maintenance of disease . The patients were given either oral dose of curcumin alone (2000, 4000, 6000, 8000, or 12,000 mg/day) or in combination with 10 mg of bioperine. 12 patients continued the treatment for 12 weeks, followed by combination treatment for five patients (one at a dose of 4000, two at 6000 mg, and two at 8000 mg) for 1 year. Further, well-controlled clinical trials with larger sample sizes are required to substantiate the efficacy of curcumin against multiple myeloma.
Dhillon et al., conducted a phase II clinical trial in 25 advanced pancreatic cancer patients . An oral dose of 8000 mg of curcumin was given every day until disease progression, with restaging performed every 2 months. Low, steady-state levels of curcumin and its conjugates were detected in the peripheral circulation for the first 4 weeks with a peak at 2242 ng/mL. In two patients, a biological effect was seen and in one the disease was maintained stably for 18 months. Remarkably, a significant but brief tumor regression was seen in one patient with a concomitant increase in serum cytokine levels. NF-κB, COX-2, and STAT3 suppression in peripheral mononuclear cells was also observed in the patients. Although oral curcumin was found to be safe and well-tolerated, poor bioavailability still remains an issue, which partly explains the biologic activity observed only in some patients. In another open-label, phase II trial, a combination of curcumin and gemcitabine was tested in advanced pancreatic cancer patients . Seventeen patients were administered 8000 mg of curcumin orally every day for 4 weeks while 1000 mg/m3 of gemcitabine were given intravenously three times a week. In five patients, curcumin or the whole treatment was discontinued due to toxicity and one patient died suddenly. In the remaining 11 patients, a partial response was seen; four had stable disease while in six the tumor progressed. Tumor progression time was 112 months, with overall survival time of 124 months, indicating a modest efficacy of the combination therapy. Also, the authors concluded that 8000 mg/day of curcumin with gemcitabine was above the maximum tolerated dose. In a recent phase I/II trial by Kanai et al., a similar combination of gemcitabine and curcumin was used to treat gemcitabine-resistant pancreatic cancer in 21 patients . In contrast, the combination of gemcitabine and curcumin 8000 mg/day was found to be safe and well tolerated in this study. Studies in a larger cohort are required to validate the results.
A plethora of in vitro and in vivo research together with clinical trials conducted over the past few decades substantiate the potential of curcumin as an anti-cancer agent. At the molecular level, curcumin targets numerous pathways, highlighting its ability to inhibit carcinogenesis at multiple levels and thus, potentially circumventing the development of resistance. However, there is a paucity of data to explain the underlying mechanism of its activity. Clinical trials with curcumin indicate safety, tolerability, non-toxicity (even up to doses of 8000 mg/day), and efficacy. These studies provide a solid foundation for more well-controlled studies in larger cohorts as well as open avenues for future drug development. However, curcumin activity is limited by its poor bioavailability and some possible adverse effects. The development of formulations of curcumin in the form of nanoparticles, liposomes, micelles or phospholipid complexes to enhance its bioavailability and efficacy are still in its early stages. Nonetheless, curcumin has established itself as a safe and promising molecule for the prevention and therapy of not only cancer but also other inflammation-driven diseases.
The hallmark process associated with certain types of cognitive decline is the formation in the brain of abnormal protein structures. Normally when malformed proteins are formed with the brain, the immune system sends out cells known as macrophages, which engulf and destroy the proteins. If this ordinary function fails, defective proteins accumulate in the brain and cognitive decline can follow.
That’s why I was excited to read that recent research is showing that curcumin encourages the immune system to send macrophages to the brain. A landmark clinical trial involving people with severe cognitive decline measured the effects of curcumin. Amazingly, the participants taking curcumin had significantly higher levels of dissolved abnormal proteins in their blood compared to those in the placebo group.
This study showed that curcumin has the ability to effectively pass into the brain, bind to beta-amyloid plaques and assist the body in their breakdown. Curcumin is one of the only substances known to have such a profound protective effect on the brain.
Turmeric has a long history as a healing herb and culinary spice in India. Interestingly, India has the highest percapita consumption of turmeric AND the lowest incidence of cognitive decline worldwide.
This little-known natural healer has been used for over 4,500 years to treat a variety of conditions most of us face as we age.
Research shows that its anti-inflammatory properties can prevent bone and joint pain, and in some cases, significantly reduce the effects of rheumatoid arthritis.
It has also been used in various types of treatments for dementia and traumatic brain injury.
In fact, a recent study found that curcumin may help the macrophages to clear the amyloid plaques found in Alzheimer’s disease.
But that’s not all, recently Dr. Ayyagari, a professor of ophthalmology at the University of California, San Diego discovered that curcumin may be very helpful in slowing retinal degeneration.
Referred to as “The Golden Spice”, it’s clear to see why people are recently starting to show interest in this natural wonder.
Studies Show That Turmeric Curcumin May Also Help In These Areas:
– May help naturally fight depression
– Could promote Liver, Heart & Digestive Health
– May lower blood cholesterol levels
– Could lower blood glucose levels and reverse insulin resistance
– Has been shown to have a marked ability to prevent cancer cell growth
How Can You Add Turmeric to Your Daily Diet?
The first thing you should know is that curcumin the main beneficial bioactive ingredient in turmeric is not soluble in water, but only in fats and oils. Therefore, its best to combine turmeric with healthy oils such as extra virgin olive or coconut oil whenever possible. Did you know that the main bioactive ingredient in black pepper seeds known as piperine can increase curcumin absorption by as much as 2,000%?
If you can handle it, the best way to get all of turmerics many health benefits is to consume whole fresh turmeric root mixed with a natural oil. Doing this enhances curcumins absorption into our bodies by as much as seven to eight-fold.